GlaxoSmithKline Pharmaceuticals Ltd. logo

GlaxoSmithKline Pharmaceuticals Ltd. (GLAXO)

Market Closed
5 Dec, 10:00
XNSE XNSE
2,545. 00
+34.2
+1.36%
416.26B Market Cap
60.37 P/E Ratio
48% Div Yield
159,008 Volume
40.12 Eps
2,510.8
Previous Close
Day Range
2,491.2 2,582.5
Year Range
1,921 3,515.7
Want to track GLAXO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 66 days

Summary

GLAXO closed Friday higher at ₹2,545, an increase of 1.36% from Thursday's close, completing a monthly increase of 1.98% or ₹49.4. Over the past 12 months, GLAXO stock gained 13.87%.
GLAXO is not paying dividends to its shareholders.
The last earnings report, released on Oct 27, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 12, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

GLAXO Chart

Similar

Apollo Hospitals Enterprise Ltd.
7,195.5
-0.08%
Abbott India Ltd.
28,925
+0.26%
Fortis Healthcare Ltd.
885
-0.4%
Biocon Ltd.
392.05
+0.95%
Syngene International Ltd.
636.2
-0.96%

GlaxoSmithKline Pharmaceuticals Ltd. (GLAXO) FAQ

What is the stock price today?

The current price is ₹2,545.00.

On which exchange is it traded?

GlaxoSmithKline Pharmaceuticals Ltd. is listed on XNSE.

What is its stock symbol?

The ticker symbol is GLAXO.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 48%.

What is its market cap?

As of today, the market cap is 416.26B.

When is the next earnings date?

The next earnings report will release on Feb 12, 2026.

Has GlaxoSmithKline Pharmaceuticals Ltd. ever had a stock split?

No, there has never been a stock split.

GlaxoSmithKline Pharmaceuticals Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Bhushan Akshikar CEO
XNSE Exchange
INE159A01016 ISIN
India Country
3,211 Employees
30 May 2025 Last Dividend
11 Sep 2018 Last Split
- IPO Date

Overview

GlaxoSmithKline Pharmaceuticals Limited is a pioneering pharmaceutical company with a broad global presence, engaging in the manufacturing, distribution, and trading of pharmaceutical products both in India and across the world. Renowned for its extensive range of vaccines and specialty medicines, the company caters to a wide spectrum of healthcare needs ranging from preventive vaccines to the treatment of chronic conditions. It was originally known as SmithKline Beecham Pharmaceuticals India Ltd. before rebranding to its current name in 2001. Since its establishment in 1924, GlaxoSmithKline Pharmaceuticals Limited has been committed to improving healthcare standards, with its headquarters located in Mumbai, India. The company’s product lineup addresses infectious diseases, HIV, oncology, immunology, and more, marking its standing as a leader in the pharmaceutical industry.

Products and Services

The company offers a diverse range of products and services, including:

  • Vaccines: A comprehensive portfolio targeting serious diseases, including:
    • Infanrix Hexa: A vaccine for infants against six diseases - diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and infection by Haemophilus influenzae type B.
    • Synflorix: Active immunization of infants against pneumococcal diseases and acute otitis media.
    • Havrix: For active immunization against hepatitis A virus-caused diseases.
    • Menveo: To prevent invasive meningococcal disease.
    • Boostrix: For immunization against diphtheria, tetanus, and pertussis.
    • Fluarix Tetra: For the prevention of influenza.
    • Varilrix: For active immunization against varicella.
    • Shingrix: For the prevention of Shingles and Postherpetic Neuralgia.
  • Specialty Medicines: Targeted treatments for chronic conditions, including:
    • NUCALA: For severe eosinophilic asthma.
    • TRELEGY ELLIPTA: For treating chronic obstructive pulmonary disease (COPD).
  • General Medicines: A range of treatments covering various therapeutic areas, such as:
    • AUGMENTIN and CEFTUM: Antibiotics for treating bacterial infections.
    • CALPOL: For the treatment of mild to moderate pain.
    • ELTROXIN: For hypothyroidism.
    • CCM: To treat calcium and vitamin D deficiency.
    • NEOSPORIN: For the treatment and prevention of specific bacterial skin infections.
    • Various topical treatments: Including BETNOVATE, T-BACT, TENOVATE, Flutivate, and PHYSIOGEL for different skin conditions, and Zimig for fungal skin infections.
    • COBADEX CZS: A multivitamin supplement.
    • Supacef: A bactericidal cephalosporin antibiotic.

Besides these products, GlaxoSmithKline Pharmaceuticals Limited is actively involved in developing new pharmaceuticals for infectious diseases, HIV, oncology, and immunology, demonstrating its continuous commitment to advancing healthcare and treatment solutions worldwide.

Contact Information

Address: GSK House
Phone: 91 22 2495 9595